Loading...
Approximately 25% of patients with acute ischemic stroke are ineligible for intravenous tissue plasminogen activator (IV t-PA) because the time of onset is unknown (e.g., because symptoms were noticed upon awakening from sleep). A surrogate marker confirming time from onset <4.5 hours would be valuable, potentially allowing substantially more patients to be treated. To ensure safety, a surrogate marker must have high specificity as well as a high positive predictive value. Several small single-center studies have suggested that lesion identification on diffusion-weighted imaging (DWI) but not on fluid-attenuated inversion-recovery imaging (FLAIR; DWI-FLAIR mismatch) might serve as such a marker.
In a multicenter, observational study, researc…